VXX-401, a novel anti-PCSK9 vaccine, reduces LDL-C in cynomolgus monkeys
Madeline M. Vroom(Kennedy Space Center), Jean‐Cosme Dodart, Jeanne K. Brooks(Dallas VA Medical Center), Shuang Ding(Chinese Academy of Sciences), Jonathan Wiggins(Dallas VA Medical Center), Valorie Ryan(Altimmune (United Kingdom)), Michael Hellerstein(ExxonMobil (United States)), Jaya Sahni(Dallas VA Medical Center), Maggie Lewis(Dallas VA Medical Center), Peter Powchik(Dallas VA Medical Center), Martina M. Ramos(Dallas VA Medical Center), Hanxin Lu(Dallas VA Medical Center), Matthew S Longo(Dallas VA Medical Center), Shixia Wang(Altimmune (United Kingdom)), Brett A. Thibodeaux(Dallas VA Medical Center), Justin D. Boyd(Pfizer (United States))
Cited by 23
Related Papers
Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model
|Nature Neuroscience|2002|858
Optimizing the Cell Painting assay for image-based profiling
|Nature Protocols|2023|156
JUMP Cell Painting dataset: morphological impact of 136,000 chemical and genetic perturbations
|bioRxiv (Cold Spring Harbor Laboratory)|2023|101
A multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants
|DOAJ (DOAJ: Directory of Open Access Journals)|2022|76
A Randomized First‐in‐Human Study With UB‐312, a UBITh® α‐Synuclein Peptide Vaccine
|Movement Disorders|2022|51